Takip et
Rona Yaeger
Rona Yaeger
mskcc.org üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
30342019
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
28922017
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
20092012
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
18982017
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
11972019
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer
A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ...
New England Journal of Medicine 386 (25), 2363-2376, 2022
7332022
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
6712018
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ...
Cancer discovery 8 (4), 428-443, 2018
5432018
Adoption of total neoadjuvant therapy for locally advanced rectal cancer
A Cercek, CSD Roxburgh, P Strombom, JJ Smith, LKF Temple, GM Nash, ...
JAMA oncology 4 (6), e180071-e180071, 2018
4882018
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of clinical oncology 37 (4), 286, 2019
4852019
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ...
Nature 548 (7666), 234-238, 2017
4542017
Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy
JJ Smith, P Strombom, OS Chow, CS Roxburgh, P Lynn, A Eaton, ...
JAMA oncology 5 (4), e185896-e185896, 2019
4322019
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
AR Brannon, E Vakiani, BE Sylvester, SN Scott, G McDermott, RH Shah, ...
Genome biology 15, 1-10, 2014
3612014
A rectal cancer organoid platform to study individual responses to chemoradiation
K Ganesh, C Wu, KP O’Rourke, BC Szeglin, Y Zheng, CEG Sauvé, ...
Nature medicine 25 (10), 1607-1614, 2019
3602019
Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy
J Garcia-Aguilar, S Patil, MJ Gollub, JK Kim, JB Yuval, HM Thompson, ...
Journal of clinical oncology 40 (23), 2546, 2022
3592022
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ...
Cancer research 74 (8), 2340-2350, 2014
3472014
Targeting alterations in the RAF–MEK pathway
R Yaeger, RB Corcoran
Cancer discovery 9 (3), 329-341, 2019
3372019
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from …
J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ...
Journal of Clinical Oncology 39 (4), 273, 2021
3142021
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
R Yaeger, A Cercek, EM O'Reilly, DL Reidy, N Kemeny, T Wolinsky, ...
Clinical cancer research 21 (6), 1313-1320, 2015
2882015
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
2742019
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20